News
Public · Published
Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
Profound Medical announced a supply and distribution agreement with the iMRI Division of Cook Medical to expand U.S. sales of its TULSA-PRO system through Cook's Copernicus program, while Profound keeps direct recurring treatment kit and service revenue relationships for systems Cook sells.
Published:
Updated:
What happened
Profound Medical announced a supply and distribution agreement with the iMRI Division of Cook Medical to expand U.S. sales of its TULSA-PRO system through Cook's Copernicus program, while Profound keeps direct recurring treatment kit and service revenue relationships for systems Cook sells.
Confirmed
Global impact / market context
The deal adds a second U.S. sales channel for TULSA-PRO equipment, letting Profound reach hospitals already building iMRI programs. Because Profound keeps the recurring kit and service revenue, each system sold through Cook can generate repeat income rather than a one-time equipment sale.
Analyst inference
Profound already sells through Siemens Healthineers, and adding Cook broadens distribution without building a larger direct sales force. Hospitals buying the integrated iMRI Suite, which means an MRI procedure room built for real-time image-guided treatment, may consider TULSA-PRO alongside other compatible therapies.
Analyst inference
What to watch
- Profound said it retains direct relationships for recurring TULSA-PRO treatment kit and service revenue on systems sold through Cook Medical, so watch whether those repeat payments scale with new placements. Confirmed
- Watch U.S. TULSA-PRO system placements through Cook's Copernicus program, since more installed systems would raise future kit and service revenue and show whether the added channel works. Analyst inference
- Watch whether Profound discloses sales split between its direct team and partners, and whether the Cook agreement includes minimum purchase targets or exclusivity terms that shape capital spending. Proposed